Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways

BACKGROUND: Regorafenib is an inhibitor of multiple kinases with aberrant expression and activity in neuroblastoma tumours that have potential roles in neuroblastoma pathogenesis. METHODS: We evaluated neuroblastoma cells treated with regorafenib for cell viability and confluence, and analysed treat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Subramonian, Divya, Phanhthilath, Nikki, Rinehardt, Hannah, Flynn, Sean, Huo, Yuchen, Zhang, Jing, Messer, Karen, Mo, Qianxing, Huang, Shixia, Lesperance, Jacqueline, Zage, Peter E.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7434894/
https://ncbi.nlm.nih.gov/pubmed/32457362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0905-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados